Internal Medicine · Visalia, CA
NPI
1013321496
Since 2014
Specialty
Internal Medicine
Code 207R00000X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
3335 S Fairway, Key Medical Associates
Visalia, CA, 93277
Phone (559) 735-3881
Groups this clinician bills Medicare through
Medicare paid, 2024
$62K
786 services
Medicare patients, 2024
278
Average age 73
Drug cost, 2024
$2.5M
4,387 prescriptions
Company payments, 2025
$1,036
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rajinderpal S Chahal was code 99214 (office e&m - established), 422 times for 201 patients. In total Rajinderpal S Chahal billed 786 services in 13 codes, and Medicare paid $62K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-10-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 422 | 201 | $91.20 | $38K |
| 95251 Test - Miscellaneous | Office | 189 | 78 | $24.87 | $4,701 |
| 99215 Office E&M - Established | Office | 87 | 40 | $127.62 | $11K |
| 99213 Office E&M - Established | Office | 41 | 31 | $54.51 | $2,235 |
| 99204 Office E&M - New | Office | 28 | 28 | $119.93 | $3,358 |
By year: 2022 $72K for 814 services; 2023 $66K for 787 services; 2024 $62K for 786 services.
Medicare prescription drug claims, 2024
In 2024, the drug Rajinderpal S Chahal prescribed most often to Medicare patients was Mounjaro (Tirzepatide), with 382 prescriptions and refills. In total Rajinderpal S Chahal wrote 4,387 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Mounjaro Tirzepatide | 382 | 487 | 74 | $508K |
| Ozempic Semaglutide | 378 | 434 | 65 | $402K |
| Levothyroxine Sodium Generic | 347 | 983 | 107 | $3,554 |
| Tresiba Flextouch U-200 Insulin Degludec | 248 | 439 | 67 | $178K |
| Metformin Hcl Er Metformin Hcl | 234 | 641 | 81 | $2,503 |
| Atorvastatin Calcium Generic | 224 | 627 | 68 | $2,348 |
| Xultophy 100-3.6 Insulin Degludec/Liraglutide | 219 | 354 | 50 | $373K |
| Metformin Hcl Generic | 214 | 621 | 70 | $1,858 |
| Rosuvastatin Calcium Generic | 166 | 484 | 56 | $2,100 |
| Jardiance Empagliflozin | 133 | 326 | 44 | $184K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 132 | 371 | 64 | $11K |
| Droplet Pen Needle Pen Needle, Diabetic | 104 | 333 | 44 | $4,633 |
| Trulicity Dulaglutide | 101 | 136 | 26 | $130K |
| Repatha Sureclick Evolocumab | 97 | 120 | 21 | $71K |
| Farxiga Dapagliflozin Propanediol | 83 | 181 | 23 | $98K |
Brand drugs: 2,195 claims; generic drugs: 1,888 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rajinderpal S Chahal $1,036 ($1,036 in general payments such as food, travel and fees) from 15 companies. The largest payer was Novo Nordisk Inc with $178.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 8 | $178 |
| Amgen Inc. AMGN | 8 | $171 |
| Mannkind Corporation MNKD | 3 | $102 |
| Dexcom, Inc. DXCM | 4 | $82.52 |
| Abbvie Inc. ABBV | 4 | $76.09 |
| Alexion Pharmaceuticals, Inc. AZN | 2 | $65.09 |
| Abbott Laboratories ABT | 3 | $57.96 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $54.34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $53.87 |
| Kyowa Kirin, Inc. 4151.T | 2 | $43.67 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.